PureTech Health’s $16 Insider Buy of Seaport Therapeutics Signals IPO Hype and Growth Confidence
PureTech Health’s 5% buy‑back of Seaport Therapeutics signals confidence and a potential IPO move, boosting insider value in this neuro‑psychiatric biotech.
3 minutes to read